Active Ingredients: Orlistat
Every effort has been made to ensure that the information provided by Cerner Multum, Inc. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise.
Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient.
The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.
If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist. Copyright 1996- Cerner Multum, Inc. Version: 12.
Your use of the content provided in this service indicates that you have read, understood and agree to the End-User License Agreement, which can be accessed by End-User License Agreement, which can be accessed by clicking on this link.
Top of the page This information does not replace the advice of a doctor.
Learn how we develop our content.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. In This Section. We found that energy density increased during the year of follow-up however, change in energy density was not associated with weight loss.
On the other hand, the high attendance group maintained the reduction in energy density during treatment with orlistat more successfully than the low attendance group.
A reduced energy density has been associated with weight loss in two previous studies. The PREMIER study showed improved weight loss in subjects with the largest reduction in energy density compared to the subjects with the lowest reduction.
The study by Ello-Martin et al. We found that increased protein intake was associated with improved weight loss, in line with previous data.
Dietary protein is associated with increased energy expenditure and less hunger. However, the subjects had already lost about 3 kg of weight prior to the initiation of orlistat.
This total change is in accordance with the weight reduction achieved in a sibutramine assisted weight loss program in obese males with SRBD. In this study, favourable changes in the frequency of disordered breathing events and cardio-metabolic risk factors were shown concomitant with the loss in weight.
A limitation of our study is that we did not measure the apnoea - hypo apnoea index after weight reduction.
However, most of the participants used continuous positive airway pressure for symptomatic treatment of their SRBD before weight loss was initiated. Conclusions This study showed that treatment with orlistat for 1 year in a group-based behavioural program was associated with further weight reduction after an initial weight loss.
However, dietary energy density, and intakes of saturated fat and fatty dairy products increased. MS performed all the dietary assessments and was responsible for data analysis, interpretation and manuscript preparation.